Professor Robert (Bob) Brown is Chair in Translational Oncology in the Department of Surgery and Cancer within the Faculty of Medicine at Imperial College. His post is a joint appointment between Imperial College London and Institute of Cancer Research where he is Professor of Translational Oncology in the Section of Medicine.
Professor Brown’s work focuses on epigenetics, patient stratification and drug resistance research, with a particular focus on ovarian cancer. He facilitates development of compounds which can reverse epigenetic silencing and is using molecular biomarker assays to aid the preclinical development and clinical use of these compounds. Recent research interests include the effect of DNA damaging agents on the epigenome, epigenetic targeting using CRISPR and whether systems oncology approaches can be used to monitor and stratify patients for targeted treatments.
et al., 2016, Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients, Clinical Cancer Research, Vol:23, ISSN:1557-3265, Pages:2213-2222
et al., 2016, Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer., Clinical Cancer Research, Vol:22, ISSN:1557-3265, Pages:3097-3104
et al., 2015, Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells, Clinical Epigenetics, Vol:7, ISSN:1868-7083
et al., 2015, Whole-genome characterization of chemoresistant ovarian cancer, Nature, Vol:521, ISSN:0028-0836, Pages:489-494
et al., 2014, Poised epigenetic states and acquired drug resistance in cancer, Nature Reviews Cancer, Vol:14, ISSN:1474-1768, Pages:747-753